Aim
ALBERT, TYPE 1 DIABETES
Edited by: Gaetano Santulli, Albert Einstein College of Medicine, United StatesReviewed by: Kailash Singh, Uppsala University, Sweden; Anna Casu, AdventHealth, United StatesIn a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did not show benefit on preserving residual beta cell function in new-onset type 1 diabetes. We present a 